搜索筛选:
搜索耗时0.0962秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
发布年度:
[会议论文] 作者：B.Garon,Amita Patnaik,Leena Gandhi,Natasha B.Leighl,Ani Sarkis Balmanoukian,Jonathan Wade Goldman,Joseph Paul Eder,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design...
Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer
[会议论文] 作者：Bang,Hyun-Choel Chung,Veena Shankaran,Ravit Geva,Daniel Virgil Thomas Catenacci,Shilpa Gupta,Joseph Paul Eder,
来源：2015年临床肿瘤学新进展学术研讨会 年份：2015
...
Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)
[会议论文] 作者：Edward B.Garon,Natasha B.Leighl,Naiyer A.Rizvi,George R.Blumenschein Jr.,Ani Sarkis Balmanoukian,Joseph Paul Eder,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells...
Checkmate 032:Nivolumab(N)alone or in combination with ipilimumab(I)for thetreatment of recurrent sm
[会议论文] 作者：Joseph Antonia,Jose A.Lopez-Martin,Johanna C.Bendell,Patrick Alexander Ott,Matthew H.Taylor,Joseph Paul Eder,
来源：2016年临床肿瘤学新进展学术研讨会 年份：2016
...
[会议论文] 作者：Braiteh,Joseph Paul Eder,Howard Safran,Bert H.,
来源：2015年临床肿瘤学新进展学术研讨会 年份：2015
...
相关搜索：
